RxDoctor Payments Data

Kristin Smith, PA

Physician Assistant · Beaver, PANPI 1285932228

Payments from drug & device makers

$13,372in general payments, 2019–2025

Across 777 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AbbVie$2K
  • Sanofi$2K
  • Journey Medical Corporation$803
  • Lilly USA, LLC$708
  • E.r. Squibb & Sons, L.L.C.$698
  • plus $4K from 20 others

What the payments were for

  • Consulting fees$1,0638%
  • Food & beverage$12,18891%
  • Education$1221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,372 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$70,537
Medicare patients
417
Services billed
1,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab13$177,457
OtezlaApremilast31$142,302
Dupixent SyringeDupilumab21$75,474
Dupixent PenDupilumab11$62,141
Clobetasol Propionate120$4,113
Ketoconazole232$4,075
Fluorouracil57$3,876
Clindamycin Phosphate74$3,368
Tacrolimus28$3,121
Metronidazole59$2,237
Triamcinolone Acetonide155$1,801
Desonide21$1,326
CiclopiroxCiclopirox Olamine50$1,103
Mycophenolate Mofetil13$1,071
Doxycycline Hyclate80$889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,825$177,45713 claims
AmgenOtezla$493$142,30231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Beaver

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →